Mobia Medical reported second-quarter revenue of $13.5 million [1], marking a 102% increase over the same period last year [2].
The surge reflects the rapid market adoption of the company's Vivistim paired vagus-nerve stimulation therapy. While revenue is climbing, the company continues to operate at a significant loss as it scales its commercial footprint.
Revenue in the second quarter of 2025 was $6.7 million [3]. The company said the recent growth was due to expanded sales of Vivistim and entry into new active territories [4].
Despite the top-line growth, Mobia Medical posted a loss of $21 million for the second quarter [5]. This deficit was driven largely by selling, general, and administrative expenses, which totaled $26.9 million [6]. Research and development expenses for the period were $2.3 million [7]. The company maintained a gross margin of 83.2% [8].
During a virtual conference call held on Aug. 11, CEO Richard Foust provided a positive outlook for the remainder of the year. He said the company is scaling its operations to meet demand for its nerve stimulation technology.
"We are initiating revenue guidance of $54 million to $56 million for the full year of 2026, which represents a growth of 69% to 75% over the prior year," Foust said [9].
The company is headquartered in Austin, Texas [10]. The financial results were discussed during a recorded call featuring Foust and representatives from the Gilmartin Group [11].
“Mobia Medical reported second-quarter revenue of $13.5 million, marking a 102% increase over the same period last year.”
Mobia Medical is currently in a high-growth, high-spend phase typical of medical device companies expanding their commercial reach. The significant gap between its high gross margins and its net loss indicates that the company is aggressively investing in sales and administration to capture market share for Vivistim. The success of the 2026 guidance depends on whether the current trajectory of territory expansion can outpace the high cost of customer acquisition.
